AstraZeneca commits $40m to insitro’s AI drug discovery
AstraZeneca’s new insitro collaboration starts with $40 million upfront; the much larger milestone ceiling depends on future results.
AstraZeneca and insitro announced a discovery collaboration on October 15 covering MASH, a serious liver disease, and cardiomyopathies, which affect heart muscle.
The agreement provides $40 million upfront, with up to approximately $1.46 billion in conditional milestones and additional single-digit royalties on future sales. [1][2]
Insitro will combine cellular experiments and machine learning to advance nominated targets into development candidates. AstraZeneca takes responsibility for clinical development, regulatory work and commercialization. The division of work connects computational discovery to a company able to test and develop a medicine. [1][2]
The useful distinction is between committing to a research approach and showing that it produces better treatments. This deal establishes the former. Whether a candidate reaches human trials—and then demonstrates benefit—will be the more informative next milestones. [1][2]
Sources & details 2 sources
Discuss in your voice app
Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.
Paste the brief into your voice app to discuss this reporting.Reporting sources
- insitro · Collaboration and terms
Original October 15 announcement; $40m upfront, up to approximately $1.46bn in conditional discovery, development and commercial milestones, additional single-digit royalties. This is a research agreement, not a clinical result.
- Reuters · Reporting and AstraZeneca interview
Patrick Wingrove’s October 15 report, syndicated here on October 16. Corroborates terms and includes original interview reporting with AstraZeneca R&D executive Sharon Barr; no independent audit of payments or clinical efficacy.
Images & figures
The upfront amount and maximum milestones share one dollar scale. Royalties are additional.
Euangelion · original explanatory figure · Source · Usage terms